Haemagglutinin-strain A(H1N1)

Osivax has dosed the first participant in a Phase 2a clinical trial evaluating OVX836 as a booster for its broad-spectrum influenza vaccine candidate.

Novavax has initiated a Phase 3 trial for its COVID-19-Influenza Combination (CIC) vaccine and stand-alone influenza vaccine, evaluating immunogenicity and safety.

CDC data indicates rising COVID-19 cases and predicts seasonal respiratory disease burden for 2024-2025 to be similar or slightly lower than previous season, emphasizing urgent need for vaccination.

The European Medicines Agency's CHMP has recommended 10 new medicines for marketing approval, encompassing five new drugs, one orphan drug, two biosimilars, and two generics.

The FDA has placed a clinical hold on Novavax's combination COVID-19 and influenza vaccine, along with its standalone influenza vaccine, following a serious adverse event report.